A new computational tool allows researchers to understand how the diverse cell types of the human body are made during ...

The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

For decades, scientists have explored the potential of bacteria in fighting cancer, but safety and efficacy barriers have ...

Our DNA is constantly under threat — from cell division errors to external factors like sunlight and smoking. Fortunately, ...

Neuroblastoma is a solid tumor that occurs in children. When high-risk, the disease has a poor prognosis. Decades ago, adding ...

Why retinoic acid is effective in this setting but not against primary tumors, has been speculated about for nearly 50 years. Scientists resolved the mystery, showing the drug 'hijacks' a normal ...

COUR Pharmaceuticals’ emerging platform reprograms the immune system to address the root causes of autoimmune diseases.

Messenger RNA can travel between different types of stem cells through tunnel-like structures, as revealed by a new study. By studying interactions between mouse and human stem cells, they discovered ...

Regeneron Pharmaceuticals (NASDAQ:REGN) said the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...